Our fed-batch fermentation process scale-up and optimisation consultancy delivers a rigorous, risk-based upstream technical advisory framework for translating lab and pilot-stage fed-batch workflows into robust, commercially viable biomanufacturing operations. Fed-batch systems are inherently susceptible to non-linear hydrodynamic shifts, mass transfer limitations, metabolite accumulation, shear gradients and nutrient stratification as working volume expands, often resulting in diminished titre, altered impurity profiles and compromised critical quality attributes if scaled by simplistic geometric extrapolation. Our advisory anchors scale-up criteria on physiologically relevant metrics including kLa, specific power input, mixing time, oxygen uptake rate and controlled feed regime kinetics, rather than empirical scaling rules. We collaborate cross-functionally with process development, quality and regulatory teams to define the process design space, establish qualified scale-down models and execute front-end hazard identification, protecting development timelines and mitigating costly batch failures ahead of technology transfer and capital deployment.
Our technical methodology integrates multi-physics CFD characterisation, mass and heat transfer mapping, feeding strategy rationalisation, metabolite control architecture and seed train sequencing, aligned with ICH Q8–Q12, cGMP and ISPE regulatory expectations. We systematically evaluate bottlenecks including dissolved oxygen depletion, carbon catabolite repression, osmotic stress, foam dynamics and heat removal constraints, while rationalising control recipes for pH, DO, feed dosing and induction timing to stabilise cellular physiology across scales. Deliverables include qualified scale-up rationale, process control strategy, parameter edge-case analysis, validation protocols and structured tech-transfer documentation packages tailored for inspection readiness. Our consultancy accommodates both microbial fermentation and mammalian fed-batch platforms, supporting stainless steel, single-use and hybrid bioreactor infrastructure.
This engineered approach unlocks measurable operational and commercial value by compressing process characterisation cycles, reducing the number of high-cost engineering runs at commercial scale and locking in consistent batch performance across the pilot-to-production continuum. Optimised feeding profiles and metabolic control enhance volumetric productivity, reduce by-product formation and stabilise harvest stream quality, lowering downstream purification burden and end-to-end cost of goods. The framework is inherently modular, supporting incremental process intensification, multi-product campaign flexibility and future capacity expansion, while establishing defensible scientific rationale for regulatory submissions and post-approval process changes.
We provide full lifecycle advisory engagement spanning feasibility assessment, scale-up strategy definition, experimental design supervision, tech-transfer execution, manufacturing troubleshooting and continuous process performance enhancement. Our upstream subject-matter experts remain embedded through site commissioning, batch campaign oversight and deviation root-cause analysis, transferring sustainable process knowledge to internal operational teams. This end-to-end consultancy model enables biopharma sponsors and manufacturers to deploy reproducible, audit-ready fed-batch fermentation processes that reliably preserve product quality from early clinical material generation through long-term commercial supply.
